Dyne Therapeutics, Inc.
A clinical-stage biotechnology company developing medicines for inherited muscle diseases such as Duchenne muscular dystrophy and myotonic dystrophy. Its FORCE platform delivers RNA-based therapies directly to muscle tissue. Founded in 2017 and incubated by venture firm Atlas Venture, the company takes its name from the "dyne," a unit of force in physics — a fitting nod to its mission of restoring muscle strength.
Bought 1.71M · Sold 4.00M
Bought 934.6K · Sold 1.31M
Sold 510.2K
Granted 1.11M · Bought 934.6K · Sold 4.19M
Bought 660.0K
Sold 46.5K
Bought 815.0K
Bought 700.0K
Granted 41.3K
Granted 2.02M · Sold 1.39M
Granted 325.3K · Bought 132.0K · Sold 22.1K
Granted 354.5K · Sold 155.8K
Granted 180.5K · Sold 11.3K
Granted 156.2K · Sold 2.0K
Granted 190.8K · Sold 46.3K
Granted 364.8K · Sold 250.4K
Granted 375.1K · Sold 239.3K
Granted 463.1K · Sold 339.2K
Granted 131.1K · Sold 9.5K
Bought 16.0K
Granted 16.5K · Sold 16.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kersten DirkDirector · 89 transactions | — | 21.35M | — | 1.71M | 4.00M |
| Atlas Venture Associates Opportunity I, L.P. +5 co-filers10% owner · 2 transactions | — | 9.75Mas of Sep 2020 | — | — | — |
| Atlas Venture Associates Opportunity I, L.P. +8 co-filers10% owner · 25 transactions | — | 8.05Mas of Feb 2024 | — | 934.6K | 1.31M |
| Atlas Venture Fund XI, L.P.10% owner · 1 transaction | — | 7.33Mas of Jul 2021 | — | — | — |
| Atlas Venture Associates XI, L.P. +2 co-filers10% owner · 5 transactions | — | 6.82Mas of Feb 2024 | — | — | 510.2K |
| Rhodes Jason PDirector · 102 transactions | — | 6.81M | 1.11M | 934.6K | 4.19M |
| Forbion Capital Fund IV Cooperatief U.A.10% owner · 1 transaction | — | 6.13Mas of Sep 2020 | — | — | — |
| Evnin Luke +7 co-filers10% owner · 3 transactions | — | 4.95Mas of Sep 2020 | — | — | — |
| Hurwitz EdwardDirector, 10% owner · 3 transactions | — | 4.95Mas of Sep 2020 | — | — | — |
| Kolchinsky Peter +2 co-filers10% owner · 2 transactions | — | 2.81Mas of Sep 2020 | — | 660.0K | — |
| Atlas Venture Associates Opportunity I, L.P. +5 co-filers10% owner · 2 transactions | — | 2.31Mas of Mar 2024 | — | — | 46.5K |
| Vida Ventures II-A, LLC +2 co-filers10% owner · 4 transactions | — | 2.17Mas of Sep 2020 | — | 815.0K | — |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P.10% owner · 1 transaction | — | 1.61Mas of Sep 2020 | — | — | — |
| Logos Global Management LP10% owner · 2 transactions | — | 804.4Kas of Sep 2020 | — | 700.0K | — |
| CureDuchenne Ventures, LLC10% owner · 1 transaction | — | 603.0Kas of Sep 2020 | — | — | — |
| Subramanian RomeshChief Scientific Officer, 10% owner · 1 transaction | — | 566.2Kas of Sep 2020 | 41.3K | — | — |
| Brumm Joshua TCEO & President, Director · 60 transactions | — | 546.6Kas of Mar 2024 | 2.02M | — | 1.39M |
| Cox JohnCEO & President, Director · 22 transactions | — | 440.2K | 325.3K | 132.0K | 22.1K |
| Beskrovnaya OxanaChief Scientific Officer · 42 transactions | — | 195.8Kas of Mar 2025 | 354.5K | — | 155.8K |
| Kerr DouglasChief Medical Officer · 11 transactions | — | 169.2K | 180.5K | — | 11.3K |
| Friedl-Naderer JohannaChief Commercial Officer · 11 transactions | — | 154.2K | 156.2K | — | 2.0K |
| Farwell WildonChief Medical Officer · 27 transactions | — | 143.5Kas of Aug 2024 | 190.8K | — | 46.3K |
| McNeill JonathanChief Business Officer · 50 transactions | — | 132.4Kas of Aug 2024 | 364.8K | — | 250.4K |
| High Susanna GattiChief Operating Officer · 39 transactions | — | 131.6Kas of Sep 2024 | 375.1K | — | 239.3K |
| Scalzo Richard WilliamSVP, Head of Finance & Admin. · 62 transactions | — | 122.3Kas of Mar 2025 | 463.1K | — | 339.2K |
| Lucera ErickChief Financial Officer · 5 transactions | — | 121.6K | 131.1K | — | 9.5K |
| Stehman-Breen CatherineDirector · 1 transaction | — | 115.7Kas of Sep 2020 | — | — | — |
| Posner Brian SDirector · 7 transactions | — | 24.5K | — | 16.0K | — |
| Klein Lawrence OttoDirector · 1 transaction | — | 10.7Kas of Sep 2020 | — | — | — |
| Incerti CarloDirector · 2 transactions | — | 0as of Nov 2024 | 16.5K | — | 16.5K |
| Lubner David CharlesDirector · 2 transactions | — | 0 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -6.63M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.